文献速递细菌感染、耐药与抗菌药物

确定万古霉素治疗年轻婴儿葡萄球菌感染的治疗靶标

Identifying a therapeutic target for vancomycin against staphylococci in young infants.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该回顾性研究纳入澳大利亚墨尔本皇家儿童医院0至90天龄的30例凝固酶阴性葡萄球菌或耐甲氧西林金黄色葡萄球菌菌血症婴儿,利用万古霉素肉汤微量稀释法测定MIC,并建立时间-事件药效学模型。结果显示AUC0-24≥300 mg/L·h或AUC24-48≥424 mg/L·h与细菌学治愈几率增加相关,AUC0-24在模型中表现最佳,可指导该人群万古霉素治疗。

要点

  • AUC0-24≥300 mg/L·h使细菌学治愈几率增加7.8倍。
  • AUC24-48≥424 mg/L·h使细菌学治愈几率增加7.3倍。
  • AUC0-24在药代-药效模型中表现最佳,可指导该人群治疗。

核心结论

  • AUC0-24≥300 mg/L·h或AUC24-48≥424 mg/L·h与年轻婴儿葡萄球菌血流感染细菌学治愈增加相关。

研究设计与样本

  • 回顾性收集澳大利亚墨尔本皇家儿童医院4年间0至90天龄凝固酶阴性葡萄球菌或MRSA菌血症婴儿数据。
  • 共纳入30例婴儿,28例为凝固酶阴性葡萄球菌,2例为MRSA菌血症,测定165个万古霉素浓度。
  • 对24株凝固酶阴性葡萄球菌和1株MRSA分离株进行万古霉素肉汤微量稀释法MIC测定。

主要发现

  • 凝固酶阴性葡萄球菌和MRSA分离株的万古霉素MIC中位数均为1 mg/L(凝固酶阴性葡萄球菌范围=0.5-4.0)。
  • AUC0-24≥300 mg/L·h使细菌学治愈几率增加7.8倍。
  • AUC24-48≥424 mg/L·h使细菌学治愈几率增加7.3倍。
  • AUC0-24在药代-药效模型中表现最佳。

关键数值与推荐

  • AUC0-24≥300 mg/L·h对应6小时给药间隔谷浓度>15-18 mg/L,12小时给药间隔谷浓度>10-15 mg/L。

临床怎么用

  • AUC0-24≥300 mg/L·h或AUC24-48≥424 mg/L·h可指导该人群万古霉素治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the therapeutic target of vancomycin in young infants with staphylococcal infections. METHODS: Retrospective data were collected for infants aged 0 to 90 days with CoNS or MRSA bacteraemia over a 4 year period at the Royal Children's Hospital Melbourne, Australia. Vancomycin broth microdilution MICs were determined. A published pharmacokinetic model was externally validated using the study dataset and a time-to-event (TTE) pharmacodynamic model developed to link the AUC of vancomycin with the event being the first negative blood culture. Simulations were performed to determine the trough vancomycin concentration that correlates with a 90% PTA of the target AUC24. RESULTS: Thirty infants, 28 with CoNS and 2 with MRSA bacteraemia, who had 165 vancomycin concentrations determined were included. The vancomycin broth microdilution MIC was determined for 24 CoNS and 1 MRSA isolate, both with a median MIC of 1 mg/L (CoNS range = 0.5-4.0). An AUC0-24 target of ≥300 mg/L·h or AUC24-48 of ≥424 mg/L·h. increased the chance of bacteriological cure by 7.8- and 7.3-fold, respectively. However, AUC0-24 performed best in the pharmacokinetic-pharmacodynamic model. This correlates with 24 to 48 h trough concentrations of >15-18 mg/L and >10-15 mg/L for 6- and 12-hourly dosing, respectively, and can be used to guide vancomycin therapy in this population. CONCLUSIONS: An AUC0-24 ≥300 mg/L·h or AUC24-48 ≥424 mg/L·h was associated with an increase in bacteriological cure in young infants with staphylococcal bloodstream infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gwee A, Duffull SB, Daley AJ, et al. Identifying a therapeutic target for vancomycin against staphylococci in young infants. J Antimicrob Chemother. 2022. PMID: 35037934. doi:10.1093/jac/dkab469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。